Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis
Respirology · 2023-10 · 28 (10) · 925-933
DOI: 10.1111/resp.14543 ↗At a glance
Journal article in Respirology, 2023-10. Written by Dimitrios Kalafatis and 5 co-authors. Institution: Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Arthritis, Rheumatoid, Idiopathic Pulmonary Fibrosis. Cited 8 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Boehringer Ingelheim, Karolinska Institutet, Roche.
Abstract (original language)
Background and Objective Studies of autoimmunity and anti‐citrullinated protein antibodies (ACPA) in idiopathic pulmonary fibrosis (IPF) have been confined to investigations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies which utilize synthetic peptides as surrogate markers for in vivo citrullinated antigens. We studied immune activation by analysing the prevalence of in vivo anti‐modified protein antibodies (AMPA) in IPF.
Methods
We included patients with incident and prevalent IPF ( N = 120), sex and smoking‐matched healthy controls (HC) ( N = 120) and patients with RA ( N = 104). Serum (median time: 11 months [Q1–Q3: 1–28 months] from diagnosis) was analysed for presence of antibodies towards native and posttranslational modified (citrullinated [Cit, N = 25]; acetylated [Acet, N = 4] and homocitrullinated [Carb, N = 1]) peptides derived from tenascin (TNC, N = 9), fibrinogen (Fib, N = 11), filaggrin (Fil, N = 5), histone ( N = 8), cathelicidin (LL37, N = 4) and vimentin ( N = 5) using a custom‐made peptide microarray.
Results
AMPA were more frequent and in increased levels in IPF than in HC (44% vs. 27%, p < 0.01), but less than in RA (44% vs. 79%, p < 0.01). We specifically observed AMPA in IPF towards certain citrullinated, acetylated and carbamylated peptides versus HC: tenascin (Cit (2033) ‐TNC 2025–2040 ; Cit (2197) ‐TNC 2177–2200 ; Cit (2198) ‐TNC 2177–2200 ) , fibrinogen (Cit (38,42) ‐Fibα 36–50 ; Cit (72) ‐Fibβ 60–74 ) and filaggrin (Acet‐Fil 307–324 , Carb‐Fil 307–324 ). No differences in survival ( p = 0.13) or disease progression ( p = 0.19) between individuals with or without AMPA was observed in IPF. However, patients with incident IPF had better survival if AMPA were present ( p = 0.009).
Conclusion
A significant proportion of IPF patients present with specific AMPA in serum. Our results suggest autoimmunity as a possible characteristic for a subgroup of IPF that may affect disease outcome.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
- Division of Rheumatology, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
- Thermo Fisher Scientific, Uppsala, Sweden.
- Center for Rheumatology, Academic Specialist Center, Stockholm Health Region, Stockholm, Sweden.
- Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
ORCID profiles: Dimitrios Kalafatis
Funding
- Boehringer Ingelheim
- Karolinska Institutet
- Roche
Cite
APA
Kalafatis, D., Joshua, V., Hansson, M., Mathsson-Alm, L., Hensvold, A., & Sköld, M. (2023). Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis. Respirology. https://doi.org/10.1111/resp.14543
Vancouver
Kalafatis D, Joshua V, Hansson M, Mathsson-Alm L, Hensvold A, Sköld M. Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis. Respirology. 2023. doi:10.1111/resp.14543
BibTeX
@article{Kalafatis2023,
author = {Kalafatis, Dimitrios and Joshua, Vijay and Hansson, Monika and Mathsson-Alm, Linda and Hensvold, Aase and Sköld, Magnus},
title = {Presence of anti‐modified protein antibodies in idiopathic pulmonary fibrosis},
journal = {Respirology},
year = {2023},
doi = {10.1111/resp.14543}
}
EUVIMED